Fulgent Genetics reported its third quarter 2025 financial results, showing a revenue of $84.1 million, a 17% increase year-over-year, and a GAAP loss of $6.6 million. The company raised its full-year 2025 revenue guidance to $325.0 million and expects to end the year with approximately $800.0 million in cash and investments, demonstrating strong momentum in its laboratory services and therapeutic development businesses.
https://www.tipranks.com/news/company-announcements/fulgent-genetics-raises-2025-revenue-guidance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.